Dermata Therapeutics, Inc.

NasdaqCM:DRMA Stock Report

Market Cap: US$4.8m

Dermata Therapeutics Management

Management criteria checks 3/4

Dermata Therapeutics' CEO is Gerry Proehl, appointed in Dec 2014, has a tenure of 11.75 years. total yearly compensation is $472.52K, comprised of 59.3% salary and 40.7% bonuses, including company stock and options. directly owns 21.45% of the company’s shares, worth $1.03M. The average tenure of the management team and the board of directors is 10.7 years and 5.1 years respectively.

Key information

Gerry Proehl

Chief executive officer

US$472.5k

Total compensation

CEO salary percentage59.26%
CEO tenure11.8yrs
CEO ownership21.5%
Management average tenure10.7yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Seeking Alpha • Aug 15

Dermata Therapeutics Q2 GAAP EPS of -$0.24

Dermata Therapeutics press release (NASDAQ:DRMA): Q2 GAAP EPS of -$0.24 (vs. -$0.70 Y/Y). As of Jun. 30, Dermata had $10.6M in cash. Shares -4.29% AH.
Analysis Article • Nov 22

We're Hopeful That Dermata Therapeutics (NASDAQ:DRMA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

CEO Compensation Analysis

How has Gerry Proehl's remuneration changed compared to Dermata Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$8m

Mar 31 2026n/an/a

-US$7m

Dec 31 2025US$473kUS$280k

-US$8m

Sep 30 2025n/an/a

-US$9m

Jun 30 2025n/an/a

-US$10m

Mar 31 2025n/an/a

-US$11m

Dec 31 2024US$462kUS$280k

-US$12m

Sep 30 2024n/an/a

-US$11m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$392kUS$280k

-US$8m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$9m

Dec 31 2022US$506kUS$318k

-US$10m

Sep 30 2022n/an/a

-US$10m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$1mUS$136k

-US$10m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

-US$4m

Dec 31 2020US$27kUS$27k

-US$3m

Compensation vs Market: Gerry's total compensation ($USD472.52K) is about average for companies of similar size in the US market ($USD652.98K).

Compensation vs Earnings: Gerry's compensation has increased whilst the company is unprofitable.

CEO

Gerry Proehl (67 yo)

11.8yrs
Tenure
US$472,515
Compensation

Mr. Gerald T. Proehl, also known as Gerry, is Co-founded at Dermata Therapeutics, Inc. He has been the Chief Executive Officer and President of Dermata Therapeutics, Inc. since December 2014, Chairman sinc...

Leadership Team

NamePositionTenureCompensationOwnership
Gerald Proehl
Founder11.8yrsUS$472.52k21.45%
$ 1.0m
David Hale
Co-Founder & Lead Independent Directorno dataUS$78.67k0.0017%
$ 79.9
Kyri Van Hoose
Senior VP & CFO5yrsUS$508.54k5.78%
$ 276.6k
Christopher Nardo
Senior VP & Chief Development Officer11.3yrsUS$537.11k0.00027%
$ 12.9
Sean Proehl
Associate General Counselno datano datano data
Kyra Peckaitis
Vice President of Marketingless than a yearno datano data
Maria Bedoya Toro Munera
Senior Vice President of Regulatory Affairs & Quality Assurance10.7yrsUS$27.04kno data
10.7yrs
Average Tenure
67yo
Average Age

Experienced Management: DRMA's management team is seasoned and experienced (10.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gerald Proehl
Founder12.7yrsUS$472.52k21.45%
$ 1.0m
David Hale
Co-Founder & Lead Independent Director11.8yrsUS$78.67k0.0017%
$ 79.9
Stephen Mento
Independent Director5.1yrsUS$49.67k0%
$ 0
Wendell Wierenga
Independent Director10yrsUS$55.67k0.00065%
$ 31.1
Kathleen Scott
Independent Director5.1yrsUS$60.67k0.000020%
$ 1.0
Andrew Sandler
Independent Director5.1yrsUS$54.67k0.00025%
$ 12.0
Brittany Bradrick
Independent Director4.7yrsUS$53.17k0.00025%
$ 12.0
5.1yrs
Average Tenure
70.5yo
Average Age

Experienced Board: DRMA's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 13:52
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dermata Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anthony VendettiMaxim Group